At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
DaxibotulinumtoxinA for injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections
In Brief
A Phase 2 clinical trial evaluating DaxibotulinumtoxinA for injection for Frown Lines. Completed, enrolled 61 participants across 4 sites in 2 countries.
Detailed Summary
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrown Lines
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJan 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedDec 26, 2018
Enrollment StartJan 24, 2019
Primary CompletionMar 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.5 years ago
Interventions
DaxibotulinumtoxinA for injectionbiological
Intramuscular injection